Reliant Compounded Solutions Monroe, LLC., Monroe, CT
Is Reliant Compounded Solutions Monroe, LLC. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Reliant Compounded Solutions Monroe, LLC. hold a Connecticut pharmacy license?
No license with this exact name and city was found in the Connecticut Department of Consumer Protection file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed.
Has Reliant Compounded Solutions Monroe, LLC. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 state referral letter (Mar 18, 2024) and 1 FMD-145 letter (Mar 18, 2024) for Reliant Compounded Solutions Monroe, LLC. Connecticut board disciplinary actions: not checked, because the Connecticut Department of Consumer Protection data this index reads gives license status only and does not include disciplinary actions. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Reliant Compounded Solutions Monroe, LLC.
- Former names FDA gives
- Compounded Solutions in Pharmacy, LLC
- Location
- Monroe, CT
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Mar 18, 2024
- FDA Data Dashboard inspections
- 3 inspections: 2 OAI, 1 VAI; 4 published Form 483s
- Form 483 text on this page
- 4 Form 483s, 24 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Reliant Compounded Solutions Monroe, LLC. (formerly Compounded Solutions in Pharmacy, LLC), a 503A facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Mar 18, 2024 | State referral letter | State Referral Letter Issued 03/18/2024 | Not linked by FDA |
| Mar 18, 2024 | FMD-145 letter | FMD-145 Letter Issued 03/18/2024 | Not linked by FDA |
| Aug 23, 2023 | Form 483 | 483 Issued 08/23/2023 | FDA copy (archived) |
| Aug 29, 2019 | Form 483 | 483 Issued 8/29/2019 | Not linked by FDA |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Reliant Compounded Solutions Monroe, LLC, Monroe, CT (FEI number 3012039582), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 23, 2023 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs): Voluntary Action Indicated (VAI); Monitoring of Marketed Animal Drugs, Feed, and Devices (Veterinary): Voluntary Action Indicated (VAI) | 3012039582 | 1215708 |
| Aug 29, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012039582 | 1101435 |
| Mar 3, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012039582 | 1004046 |
Form 483s FDA has published for this site
- Aug 23, 2023: Form 483 to Reliant Compounded Solutions Monroe, LLC, published Sep 22, 2023. fda.gov
- Jul 27, 2021: Form 483 to Reliant Compounded Solutions Monroe, LLC, published Oct 7, 2021. fda.gov
- Aug 29, 2019: Form 483 to Reliant Compounded Solutions Monroe, LLC, published Feb 27, 2025. fda.gov
- Apr 24, 2017: Form 483 to Reliant Compounded Solutions Monroe, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 24 numbered observations in all, across 4 inspections ending Apr 24, 2017 to Aug 23, 2023. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 1, 2023 to Aug 23, 2023: 3 observations
- Firm on the cover
- Reliant Compounded Solutions Monroe, LLC, 810 Main St, Monroe, CT 06468-2809
- FEI number
- 3012039582
- Establishment type on the cover
- Producer of Non-Sterile and Sterile Drug Products
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disruption of unidirectional airflow.
Specifically,
On August 1, 2023, while observing Pharmacist <Redacted B4> aseptically processing Triple P (Papaverine, Phentolamine, Prostaglandin) 35/1/12 Injectable lot number 08012023@ <Redacted B4>, I noted the following:
• Phaimacist <Redacted B4> was noted wiping down needed materials with <Redacted B4> and then "tossing" these materials into the BSC (ISO 5).
• Phaimacist <Redacted B4> was noted make rapid movements within the BSC (ISO 5) while preparing the compounded drug product.
Observation 2
Smoke studies were inadequately performed under dynamic conditions.
Specifically,
On June 2023 and December 2022, the firm had conducted airflow pattern studies (smoke studies) on the Hazardous BSC, Non-Hazardous BSC and the <Redacted B4> which did not adequately demonstrate dynamic sterile compounding operations in that videos presented were brief (studies <Redacted B4>), did not contain enough smoke to demonstrate airflow over sterile compounding operations and did not demonstrate that the airflow was not intenupted during movement by compounding personnel.
This is a repeat of Observation 9 from FDA 2019 Inspection (8/06/2019 -08/29/2019)
Observation 3
Sterile drugs were exposed to lower than ISO 5 quality air.
Specifically,
Stock solutions were stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.
For example, the sterile compounding log shows that on 06/07/2023 a batch of Dexamethasone 12mg/mL Preservative Free (PF) stock solution was produced using <Redacted B4> <Redacted B4> in the ISO 5 Cleanroom hood and was assigned lot number 06072023 <Redacted B4> with BUD of 9/05/2023. The stock solution is stored within the refrigerator in the unclassified Storage Room. The firm has conducted <Redacted B4> punctures of the stock solutions from June to July to compound Dexamethasone OPHTH (PF) 0.01 % and0. l % Solutions after which the firm had placed the stock solution back into the unclassified Stock Room refrigerator.
Inspection Jul 20, 2021 to Jul 27, 2021: 7 observations
- Firm on the cover
- Compounded Solutions in Pharmacy, LLC, 810 Main St, Monroe, CT 06468-2809
- FEI number
- 3012039582
- Establishment type on the cover
- Producer of Non-Sterile and Sterile Drug
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Materials or supplies were not disinfected prior to entering the aseptic processing areas.
Specifically, on 7/ 22/ 2021, a cleanroom operator was observed not disinfecting individually packaged supplies and drug vials immediately prior to them being introduced into the ISO 5 area for any of the observed prescriptions prepared such as Timolol/Brimonidine Ophth PF 0.5%-0.2% Solution (Lot# 07222021@40; BUD 7/ 25/ 2021), Testosterone (AQ) Ophth PF 0.03% Suspension (Lot# 07222021@28; BUD 7/ 25/ 2021), and Triple P 15/ 0.5/ 10 Injectable (Lot# 07222021@50; BUD 10/ 20/ 2021).
Observation 2
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Specifically, on 7/ 22/ 2021, a clean room operator was observed al low ing the sleeves of the gown being donned to touch the floor of the ISO 7 buffer room during the gowning process. That operator then proceeded with that same gow n to aseptically fill Testosterone (AQ) Ophth PF 0.03% Suspension (Lot# 07222021@28; BUD 7/ 25/ 2021), a process that requires him to extend his gloved hands and gowned arms into the ISO 5 hood.
Observation 3
The use of sporicidal agents in the clean rooms and ISO 5 classified aseptic processing area was inadequate.
Specifically, Section 8.4.1 of the SOP# 3.020, entitled, "Cleaning and Maintenance of the Clean Room Facility" allows <Redacted B4> cleaning to be performed with either the sterile <Redacted B4> for the non-hazardous BSC. The firm does not use sporicida l cleaning agents in the ISO 8 Anteroom.
Observation 4
Inadequate pressure differentials between higher quality air rooms and lower qualit y air rooms were observed.
Specifically, the cleanroom differential pressure for the Non-Hazardous Sterile Compounding Room and the Anteroom were observed with a differential pressure reading of <Redacted B4> from 11/ 2/ 2020 thru 12/ 16/ 2020 and from 2/ 16/ 2021 thru 2/ 17/ 2021, respectively. Per SOP# 3.010, entitled, "Sterile Compounding Area Requirements", the minimum differential positive pressure gauge reading for physical separations between nonhazardous controlled areas is <Redacted B4> of the water column. No investigation was initiated by the firm to assess the impact on the sterile drug products produced during the differential pressure excursion. The follow ing are examples of sterile drug products produced during the differential pressure excursion timeframes: Triple P 30/ 3/ 40 Injectable (Lot# 12012020@46; BUD 2/ 25/ 2021); <Redacted B4> (Lot # <Redacted B4>; BUD 11/ 23/ 2020); and Doxycycline Ophth 0.025% Solution (Lot# 11172020@42; BUD 11/ 20/ 2020).
Observation 5
Cleaning practices used by the firm for cleaning of ISO 5 areas do not support appropriate environmental cleanliness for sterile drug production.
Specifically,
(A) On 7/ 22/ 2021, sterile wipes used to clean the ISO 5 area were observed exposed to condit ions worse than ISO Class 5 air quality. The opened packet of sterile wipes were observed left on top of a container and exposed to ISO 7 environment. These wipes were used to clean the ISO 5 area between batches and after production.
(B) On 7/ 23/ 2021, the technician <Redacted B4> who performed <Redacted B4> cleaning of the Compounding <Redacted B4> in the Biohazard Room was observed with his head and arm inside the <Redacted B4> while performing cleaning of the equipment's back walls, thereby, exposing non-sterile garbs inside the ISO Class 5 <Redacted B4>. The technician <Redacted B4> was also observed with exposed skin around the face and with his face and exposed skin inside of the ISO 5 area. ...
Observation 6
The firm held product in conditions that does not ensure the integrity of the finished drug product and could therefore be injurious to health.
Specifically, we observed the firm deviated from manufacturer instructions in the <Redacted B4> (NDC: <Redacted B4> package insert without adequate scientific rationale to ensure the integrity of the finished drug product in <Redacted B4> order to prevent any degradation, impurities, or different strength than the label claim. The firm stores the reconstituted drug product in <Redacted B4> at a temperature above the recommended temperature in the manufacturer's label <Redacted B4>. In addition, the firm uses the reconstituted <Redacted B4> as a stock solution and <Redacted B4> the solution after a <Redacted B4> cycle; however, the manufacturer's labeling states the product should not be <Redacted B4> once <Redacted B4>. <Redacted B4> per vial (Lot# ) was reconstituted on February 17, 2021 for the production of <Redacted B4> Lot <Redacted B4> ) and the reconstituted stock vial was assigned a beyond-use date of May 18, 2021. ...
Observation 7
Personnel engaged in non-sterile compounding did not ensure the prevention of contamination of compounded products with foreign matter.
Specifically, operators performed non-sterile drug compounding on a countertop in uncontrolled space, without the appropriate clothing for the compounding performed (e.g., facemask, hair bonnet).
Inspection Aug 6, 2019 to Aug 29, 2019: 9 observations
- Firm on the cover
- Compounded Solutions in Pharmacy, 810 Main St, Monroe, CT 06 468 -2809
- FEI number
- 3012039582
- Establishment type on the cover
- Producer of Non-Sterile and Sterile Drug Products
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 021 80
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You used a non-pharmaceutical grade component in the formulation of a drug product.
Specifically, your firm failed to appropriately use drug substances that are components of approved drugs or ingredients to produce sterile and non-sterile drug products. For example:
On 8/6/2019, a partially used reconstituted I-gram vial of Ceftazidime for Injection USP was found in your firm's stock refrigerator. The Ceftazidime for Injection (NDC 44567-235-25) Lot 06072019 <Redacted B4> vial was reconstituted with <Redacted B4> of <Redacted B4> on 6/7/19 and assigned a 90-day BUD. The reconstituted vial was subsequently used for sterile to sterile production of <Redacted B4> drug products eye drops and <Redacted B4> intravitreal products) on 6/7 /19, 6/11/19, 7/8/19, and 8/5/19, and each drug product was assigned a 14-day BUD. According to the Ceftazidime package insert, Ceftazidime for Injection is supplied as a "single-dose viaI" and "Ceftazidime for injection, when constituted as directed with Sterile Water for Injection or Bacteriostatic Water for Injection maintains satisfactory potency for 12 hours at room temperature or for 3 days under refrigeration. ...
Observation 2
The ISO 5 classified aseptic processing areas had difficult to clean, particle-generating and visibly dirty equipment or surface.
Specifically,
Your firm's hazardous ISO Class 5 BSC, <Redacted B4> was observed to have what appeared to be duct tape along the entire circumference of the shield frame grove adhering the <Redacted B4> fame grove adhering the iframe to the <Redacted B4> sash (shield). Several cracks were observed in the <Redacted B4> sash (shield) as well. Your firm's non-hazardous ISO Class 5 BSC <Redacted B4> was observed to have scratching on the inside of the <Redacted B4> sash (shield) as well as rouging on the <Redacted B4> deck.
- Your firm uses <Redacted B4> caulking guns inside ISO Class 5 BS Cs to perform <Redacted B4> of multiple <Redacted B4> drug products such as Triple P Injection, Double P Injection, DMSO Injection, and several other drug products containing oils. Firm personnel use the caulking guns to compress syringes with attached <Redacted B4> because <Redacted B4> compression of syringes with attached <Redacted B4> is difficult. The caulking guns were observed to be stored (hanging on a shelving unit) in the non-hazardous ISO Class 7 buffer room. ...
Observation 3
Non-microbial contamination was observed in your production area.
Specifically,
On 8/6/2019, rust was observed on the exterior of both the hazardous and non-hazardous ISO Class 5 BSCs. In addition, on 8/7/2019 and 8/8/2019, rust was observed on a chain attached to the top of the non-hazardous ISO Class 5 BSC <Redacted B4>. The rusty chain was observed stored on a horizontal ledge on the front of the non-hazardous ISO Class BSC and is used to prop open the <Redacted B4>, sash (shield) during cleaning of the non-hazardous ISO Class 5 BSC. A hook at the end of the chain aligned with the scratching on the inside of the sash (shield) of the ISO Class 5 BSC ). <Redacted B4>
Observation 4
Unsealed, loose ceiling tiles were observed in your cleanroom.
Specifically,
Ceiling tiles, including ceiling mounted lights and HEPA filters, located in both the firm's ISO Class 7 non-hazardous buffer room and ISO Class 7 hazardous buffer room, were observed unsealed or with caulking which appeared to be pealing back or not properly adhered. In addition, paint on the comers of ceiling tiles/lights in the firm's ISO Class 7 non-hazardous buffer room appeared to be chipped and or flaked off. The firm's ISO Class 7 non-hazardous buffer room supports an ISO Class 5 BSC <Redacted B4> used to produce non-hazardous sterile drug products such as Triple P Injection and the firm's ISO Class 7 hazardous buffer room supports an ISO Class 5 BSC <Redacted B4> used to produce hazardous drug products such as Testosterone AQ (PF) suspensi
Deficiencies regarding loose and or unsealed cleanroom ceiling tiles was also noted during the 2017 FDA inspection.
Observation 5
The ISO 5 classified aseptic processing area was located within a non-classified room (segregated production area).
Specifically,
Your firm's ISO Class <Redacted B4> an ISO Tech <Redacted B4> is in an unclassified room. Firm personnel open the ISO Class <Redacted B4> to perform cleaning, exposing the inside of the <Redacted B4> to the unclassified air in the suncunding room. Your firm uses this <Redacted B4> exclusively to produce sterile autologous semm eye drops and since 10/23/2018, your firm has produced <Redacted B4> lots of sterile autologous semm eye drops. Autologous semm eye drops are assigned 90 day beyond use dates (BUD).
Your firm's ISO Class <Redacted B4> an ISO Tech <Redacted B4> is in an unclassified room. Firm personnel open the ISO Class <Redacted B4> to perform cleaning, exposing the inside of the <Redacted B4> to the unclassified air in the suncunding room. Your firm uses this <Redacted B4> exclusively to produce sterile autologous semm eye drops and since 10/23/2018, your firm has produced <Redacted B4> lots of sterile autologous semm eye drops. Autologous semm eye drops are assigned 90 day beyond use dates (BUD).
Observation 6
Disinfecting agents and used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically,
Cleaning practices and disinfecting agents used by the firm for cleaning of ISO Class 5 areas such as the firm's BSCs and <Redacted B4> are not adequate and do not support appropriate environmental cleanliness for sterile drug production. The firm uses <Redacted B4> ml from manufacture <Redacted B4>, however, this cleaning agent is not labeled as sterile. In addition, firm personnel who peiform cleaning of critical ISO Class 5 BSCs bend at the waist and reach into and or enter the ISO Class 5 BSCs to perform cleaning of the equipment's back and side walls instead of using an extension mop/wipe handle, therefore exposing non-sterile gowning and exposed skin into the critical ISO Class 5 areas.
Observation 7
The use of sporicidal agents in the ISO 5 classified aseptic processing area was inadequate.
Specifically,
Your firm does not follow manufacturer recommended dwell times for sporicidal cleaning agents used within ISO Class 5 critical environments to assure elimination of spore forming microbes. Firm personnel use <Redacted B4> to perform cleaning of the firm's ISO Class 5 BSCs and ISO Class 5 <Redacted B4>, however, sporicidal dwell times as identified by the cleaning agent manufacturer is not followed. For example: per <Redacted B4> the minimum efficacy data for <Redacted B4> as <Redacted B4> for sporicidal. Your firm personnel use <Redacted B4> with only a <Redacted B4> contact time, and in addition, your firm personnel do not reapply cleaning agents when ISO Class 5 surfaces appear dry prior to reaching the manufacturer's recommended dwell time.
personnel use --.ii-a...&..--' to perform cleaning ofthe firm's ISO Class 5 BSCs and ISO Class 5 .._.....__.____. however, sporicidal dwell times as identified by the cleaning agent manufacturer is not followed. For example: per.._.1.11....__,___ , the minimum efficacy data for.._.....__.__ ___. is11e1l"'W'.ll.-..... for sporicidal. ...
Observation 8
You produced beta-lactam drugs without providing adequate cleaning of work surfaces and cleaning of personnel to prevent cross-contamination.
Specifically,
Your firm reconstitutes and utilizes beta-lactam drugs, such as cephalosporins (e.g. Ceftazidime), to produce sterile drug products. Your firm has not established and does not follow specific standard operating procedures to prevent and or mitigate the risk of cross-contamination between beta-lactams and other sterile products produced within your firm's non-hazardous ISO Class 5 BSC <Redacted B4> . For example, your firm has not determined the suitability of the cleaning agents used to decontaminate beta-lactam residues or spills remaining in the ISO-5 BSC following production of sterile drug products such as Ceftazidime eye drops.
Observation 9
You had inadequate HEP A filter coverage and airflow over the area to which sterile product was exposed.
Specifically,
Your firm's smoke studies conducted within the ISO Class 5 areas are inadequate. The studies were conducted <Redacted B4> under dynamic conditions in July 2019; however, the smoke study videos only include syringe to syringe transfer/mixing of sterile drug products and did not include the transfer of starting components and materials into the ISO Class 5 areas, transfer of product into final container closure systems, or retrieval of product from the ISO Class 5 areas to demonstrate unidirectional airflow and sweeping action over and away from sterile product under dynamic conditions.
Inspection dated Apr 24, 2017 by FDA (dates on the form not read): 5 observations
- Firm on the cover
- Compounded Solutions in Pharmacy, LLC 810 Main Street, Producer ofSterile and Non-Sterile Drugs Monroe, CT 06468
- FEI number
- 3012039582
- FDA district office on the cover
- 02/22-24/2017; 02/28/2017; 03/01-03/2017 One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Clothing of personnel engaged in the manufacture of drug products is not appropriate for the duties they perform. Specifically, the pharmacist observed producing Triple P 10/0.5/16.6 Injectable Lot No. 022320 17@8 on 02/23/2017 donned a disposable, non-sterile lab coat, rated for working in an ISO 7 environment, and sterile gloves with out sterile sleeves. The pharmacist was observed to extendREDACTED (b)(6) forearms exposing the ISO 5 production environment and product to the non-sterile lab coat.
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically: A. Your environmental monitoring program is deficient in that you do not perform monitoring of your classified spaces, including your ISO 5 working space and of personnel on a daily basis, rather it is performed REDACTED (b
)( 4) and REDACTED (b)(4) , respectively. This frequency is not sufficient to demonstrate conditions are consistently maintained.
B. Your firm does not continuously monitor the pressure differentials in your IS08, ISO 7 and ISO 5 sterile production space in order to demonstrate that conditions are maintained throughout the operation. For example, continuous monitoring was not observed during the production ofTriple P 10/0.5/16.6 Injectable Lot No. 02232017@8 on 02/23/2017.
EMPI..OVEE(S) NAME AND Tm..E (Prmfor T)t»)
OATEISSUED
Observation 3
Aseptic processing areas are deficient in that ceilings are not smooth and/or hard surfaces that are not easily cleanable.
Specifically, on 02/23/2017 during the production of Triple P 10/0.5/16.6 Injectable Lot No. 02232017@8, unsealed ceiling tiles were noted in your ISO 7 clean room where your ISO 5 REDACTED (b)(4) are located, and chipped/ peeling caulking was noted on the ceiling tile in the adjacent ISO 8 ante-room where the REDACTED (b)(4) of this Triple P lot: Papaverine HCL U SP , Phentolamine REDACTED (b)(4) Prostaglandin E1 READCTED (b) (4) occurred.
Observation 4
Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity ofthe drug product.
Specifically, before the production of Triple P 10/0.5/16.6 Injectable Lot No. 022320 17@8 on 02/23/2017 it was noted that the pharmicist intended to use what appeared to be the same non-disposable, REDACTED (b)(4 ) that he had used the previous da y to REDACTED (b)(4 ) Prosta glandin E1 REDACTED (b)(4) for Triple P 30/1/10 Injectable Lot No. 0222017@13 without adequately washin g it be fore u se (e.g. with REDACTED (b)(4).
The REDACTED (b)(4) was only REDACTED (b)(4) The pharmacis t stated this was a typical practic e. T he p harmacist then procur ed a new REDACTED (b)(4) and proceeded to produce Triple P 10/0.5/16.6 Injectable Lot No. 022320 17 @8 on 0 2/2 3/2 01 7, and used the same non-disposal, REDACTED (B) (4) to REDACTED (b)(4): Papaverine HCL USP, Phen to la mine 15 4 Prostaglandin E1 REDACTED (b)(4) with out washing in between, only REDACTED (b)(4) The owner stated this was per the SOP, no data was provided to demonstrate this practice is adequate for cleaning the REDACTED (b)(4).
Observation 5
The separate or defined areas necessary to prevent contamination or mix-ups are deficient. S
pecifically, on 02/23/2017 the production of Progesterone SR 75mg capsules, Lot No. 02232017@10 was observed to take place on a lab bench in the general laboratory and not in a laminar flow hood REDACTED (b)(4) At the same time on the same bench, Thyroid (60mg) 1 grain capsules, Lot No. 02222017@31 were being produced in the general laboratory and not in a LFH REDACTED (b)(4). No other containment was provided.
State board of pharmacy records
No license with this exact name and city was found in the Connecticut Department of Consumer Protection file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.
What this covers: The dataset gives each license’s status and status reason in the department’s words but lists no disciplinary actions, so Connecticut board actions are not checked.
Close but not exact matches
These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.
- Compounded Solutions in Pharmacy LLC, Monroe, CT: fda gives one as the former name of the other.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Connecticut Department of Consumer Protection license file
Records last pulled Nov 15, 2026. Every entry links to the original public record.